Evaluation of the American Heart Association cardiovascular disease prevention guideline for women
- PMID: 20160160
- PMCID: PMC2841216
- DOI: 10.1161/CIRCOUTCOMES.108.842385
Evaluation of the American Heart Association cardiovascular disease prevention guideline for women
Abstract
Background: The 2007 update to the American Heart Association (AHA) guidelines for cardiovascular disease prevention in women recommend a simplified approach to risk stratification. We assigned Women's Health Initiative participants to risk categories as described in the guideline and evaluated clinical event rates within and between strata.
Methods and results: The Women's Health Initiative enrolled 161 808 women ages 50 to 79 years and followed them prospectively for 7.8 years (mean). Applying the 2007 AHA guideline categories, 11% of women were high risk, 72% at-risk, and 4% at optimal risk; 13% of women did not fall into any category, that is, lacked risk factors but did not adhere to a healthy lifestyle (moderate intensity exercise for 30 minute most days and <7% of calories from saturated fat). Among high risk, at-risk, and optimal risk women, rates of myocardial infarction/coronary death were 12.5%, 3.1%, and 1.1% per 10 years (P for trend <0.0001); the event rate was 1.3% among women who could not be categorized. We observed a graded relationship between risk category and cardiovascular event rates for white, black, Hispanic, and Asian women, although event rates differed among ethnic groups (P for interaction=0.002). The AHA guideline predicted coronary events with accuracy similar to current Framingham risk categories (area under receiver operating characteristic curve for Framingham risk, 0.665; for AHA risk, 0.664; P=0.94) but less well than proposed Framingham 10-year risk categories of <5%, 5% to 20%, and >20% (area under receiver operating characteristic curve for Framingham risk, 0.724; for AHA risk, 0.664; P<0.0001).
Conclusions: Risk stratification as proposed in the 2007 AHA guideline is simple, accessible to patients and providers, and identifies cardiovascular risk with accuracy similar to that of the current Framingham algorithm. Clinical Trial Registration- clinicaltrials.gov. Identifier: NCT00000611.
Figures

Comment in
-
The female heart is vulnerable to cardiovascular disease: emerging prevention evidence for women must inform emerging prevention strategies for women.Circ Cardiovasc Qual Outcomes. 2010 Mar;3(2):118-9. doi: 10.1161/CIRCOUTCOMES.110.942664. Circ Cardiovasc Qual Outcomes. 2010. PMID: 20233978 No abstract available.
Similar articles
-
Juggling Multiple Guidelines: A Woman's Heart in the Balance.J Womens Health (Larchmt). 2016 Mar;25(3):213-21. doi: 10.1089/jwh.2015.5467. Epub 2016 Jan 15. J Womens Health (Larchmt). 2016. PMID: 26771424
-
Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative.JAMA Intern Med. 2018 Sep 1;178(9):1231-1240. doi: 10.1001/jamainternmed.2018.2875. JAMA Intern Med. 2018. PMID: 30039172 Free PMC article.
-
Twelve-year follow-up of American women's awareness of cardiovascular disease risk and barriers to heart health.Circ Cardiovasc Qual Outcomes. 2010 Mar;3(2):120-7. doi: 10.1161/CIRCOUTCOMES.109.915538. Epub 2010 Feb 10. Circ Cardiovasc Qual Outcomes. 2010. PMID: 20147489 Free PMC article.
-
What do the 2011 American Heart Association guidelines tell us about prevention of cardiovascular disease in women?Clin Cardiol. 2011 Sep;34(9):520-3. doi: 10.1002/clc.20940. Clin Cardiol. 2011. PMID: 21905040 Free PMC article. Review.
-
Representation of women in randomized clinical trials of cardiovascular disease prevention.Circ Cardiovasc Qual Outcomes. 2010 Mar;3(2):135-42. doi: 10.1161/CIRCOUTCOMES.110.868307. Epub 2010 Feb 16. Circ Cardiovasc Qual Outcomes. 2010. PMID: 20160159 Review.
Cited by
-
Predictors of cardiovascular risk in women.Womens Health (Lond). 2013 Sep;9(5):491-8. doi: 10.2217/whe.13.44. Womens Health (Lond). 2013. PMID: 24007254 Free PMC article. Review.
-
Contributions of the Women's Health Initiative to Cardiovascular Research: JACC State-of-the-Art Review.J Am Coll Cardiol. 2022 Jul 19;80(3):256-275. doi: 10.1016/j.jacc.2022.05.016. J Am Coll Cardiol. 2022. PMID: 35835498 Free PMC article. Review.
-
European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).Int J Behav Med. 2012 Dec;19(4):403-88. doi: 10.1007/s12529-012-9242-5. Int J Behav Med. 2012. PMID: 23093473 No abstract available.
-
High prevalence of subclinical atherosclerosis in Brazilian postmenopausal women with low and intermediate risk by Framingham score.Int J Cardiovasc Imaging. 2017 Mar;33(3):401-410. doi: 10.1007/s10554-016-1002-1. Epub 2016 Oct 20. Int J Cardiovasc Imaging. 2017. PMID: 27766451
-
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association.J Am Coll Cardiol. 2011 Mar 22;57(12):1404-23. doi: 10.1016/j.jacc.2011.02.005. J Am Coll Cardiol. 2011. PMID: 21388771 Free PMC article. No abstract available.
References
-
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment panel III) final report. Circulation. 2002;106:3143–3421. - PubMed
-
- Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr, Stone NJ, National Heart, Lung, and Blood Institute. American College of Cardiology Foundation. American Heart Association Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239. - PubMed
-
- Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of Coronary Heart Disease Using Risk Factor Categories. Circulation. 1998;97:1837–1847. - PubMed
-
- D'Agostino RB, Grundy S, Sullivan LM, Wilson P, CHD Risk Prediction Group Validation of the Framingham Coronary Heart Disease Prediction Scores. Results of a Multiple Ethnic Groups Investigation. JAMA. 2001;286:180–187. - PubMed
-
- Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D'Agostino RB, Levy D. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol. 2004;94:20–24. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
- N01WH42129-32/WH/WHI NIH HHS/United States
- N01WH32100-2/WH/WHI NIH HHS/United States
- N01 WH022110/WH/WHI NIH HHS/United States
- N01WH32108-9/WH/WHI NIH HHS/United States
- N01WH32122/WH/WHI NIH HHS/United States
- N01WH32105-6/WH/WHI NIH HHS/United States
- N01WH32111-13/WH/WHI NIH HHS/United States
- N01WH32118-32119/WH/WHI NIH HHS/United States
- N01WH24152/WH/WHI NIH HHS/United States
- N01 WH042108/WH/WHI NIH HHS/United States
- N01WH42107-26/WH/WHI NIH HHS/United States
- N01WH32115/WH/WHI NIH HHS/United States
- N01WH44221/WH/WHI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical